Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?. Issue 2 (February 2015) - Choi, Yong Won
Highlights Fourth-line therapy in advanced NSCLC is clinical practice in some countries. Median overall survival after the start of fourth-line therapy was 9 months. Good performance status was favorable prognostic factor after fourth-line therapy. Disease control after first-line therapy was associated with favorable outcome.